{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:26:28Z","timestamp":1791213988080,"version":"4.1.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult T-cell leukemia (ATL) and human T-cell lymphotropic virus type I (HTLV-I)\u2013associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) are known to be caused by HTLV-I infection. However, current methods used to determine HTLV-I infection do not differentiate between HTLV-I asymptomatic carriers (ACs) and ATL and HAM\/TSP patients. Using the luciferase immunoprecipitation system, a highly sensitive, quantitative technology that can efficiently detect HTLV-I Ab responses, we examined Ab responses for HTLV-I in serum\/plasma samples from 439 subjects in Jamaica, including HTLV-I\u2013seronegative donors, ACs, and ATL and HAM\/TSP patients. The Ab responses of HTLV-I\u2013infected subjects differed significantly from those of seronegative donors for all 3 immunodominant proteins, Gag, Env, and Tax. HAM\/TSP patients had significantly higher Ab responses for Gag and Env compared with ACs, and Ab responses for all 3 Ags were higher in HAM\/TSP patients than in ATL patients. Moreover, immunoreactivities for HTLV-I Ags as determined by the luciferase immunoprecipitation system could distinguish HAM\/TSP patients from ACs at a true-positive rate of 85.42% and from ATL patients at a true-positive rate of 75.00%, and modeled in conjunction with subject information to distinguish HAM\/TSP patients from ACs (odds ratio = 14.12) and from ATL patients (odds ratio = 7.00). The relative risk assessment resulting from these significant differences between Ab responses in HTLV-I\u2013infected groups may be a useful diagnostic tool in the future.<\/jats:p>","DOI":"10.1182\/blood-2011-11-390807","type":"journal-article","created":{"date-parts":[[2012,2,8]],"date-time":"2012-02-08T07:20:40Z","timestamp":1328685640000},"page":"2829-2836","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM\/TSP patients from Jamaica"],"prefix":"10.1182","volume":"119","author":[{"given":"Yoshimi","family":"Enose-Akahata","sequence":"first","affiliation":[{"name":"Viral Immunology Section, Neuroimmunology Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Abrams","sequence":"additional","affiliation":[{"name":"Viral Immunology Section, Neuroimmunology Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kory R.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Information Technology & Bioinformatics Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Maloney","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II, Office of Surveillance and Epidemiology, Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Viral Immunology Section, Neuroimmunology Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111807383599000_B1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.bloodjournal503481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases.","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"issue":"12","key":"2019111807383599000_B2","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.","volume":"77","author":"Poiesz","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2019111807383599000_B3","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","article-title":"Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.","volume":"79","author":"Yoshida","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8452","key":"2019111807383599000_B4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(85)92734-5","article-title":"Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.","volume":"2","author":"Gessain","year":"1985","journal-title":"Lancet"},{"issue":"8488","key":"2019111807383599000_B5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(86)91298-5","article-title":"HTLV-I associated myelopathy, a new clinical entity.","volume":"1","author":"Osame","year":"1986","journal-title":"Lancet"},{"issue":"2","key":"2019111807383599000_B6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0002-9394(14)73974-1","article-title":"Uveitis associated with human T-cell lymphotropic virus type I.","volume":"114","author":"Mochizuki","year":"1992","journal-title":"Am J Ophthalmol"},{"issue":"8635","key":"2019111807383599000_B7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0140-6736(89)90038-X","article-title":"Chronic inflammatory arthropathy associated with HTLV-I.","volume":"1","author":"Nishioka","year":"1989","journal-title":"Lancet"},{"issue":"8673","key":"2019111807383599000_B8","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(89)91793-5","article-title":"HTLV-1 and polymyositis in Jamaica.","volume":"2","author":"Morgan","year":"1989","journal-title":"Lancet"},{"issue":"39","key":"2019111807383599000_B9","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1038\/sj.onc.1208968","article-title":"Global epidemiology of HTLV-I infection and associated diseases.","volume":"24","author":"Proietti","year":"2005","journal-title":"Oncogene"},{"issue":"5","key":"2019111807383599000_B10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0197-2456(01)00153-2","article-title":"Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.","volume":"22","author":"De Gruttola","year":"2001","journal-title":"Control Clin Trials"},{"key":"2019111807383599000_B11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-4690-2-27","article-title":"Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL).","volume":"2","author":"Matsuoka","year":"2005","journal-title":"Retrovirology"},{"issue":"3","key":"2019111807383599000_B12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11481-010-9216-9","article-title":"Neuroimmunity of HTLV-I Infection.","volume":"5","author":"Matsuura","year":"2010","journal-title":"J Neuroimmune Pharmacol"},{"issue":"6","key":"2019111807383599000_B13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3109\/13550289809114225","article-title":"Analysis of HTLV-I proviral load in 202 HAM\/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM\/TSP.","volume":"4","author":"Nagai","year":"1998","journal-title":"J Neurovirol"},{"issue":"4","key":"2019111807383599000_B14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.20144","article-title":"Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia\/lymphoma in asymptomatic carriers.","volume":"110","author":"Okayama","year":"2004","journal-title":"Int J Cancer"},{"issue":"6","key":"2019111807383599000_B15","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ijc.2910430603","article-title":"The prevalence of antibody to p42 of HTLV-I among ATLL patients in comparison with healthy carriers in Japan.","volume":"43","author":"Yokota","year":"1989","journal-title":"Int J Cancer"},{"issue":"2","key":"2019111807383599000_B16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<196::AID-IJC12>3.0.CO;2-G","article-title":"Antibody reactivities to tumor-suppressor protein p53 and HTLV-I Tof, Rex and Tax in HTLV-I-infected people with differing clinical status.","volume":"71","author":"Chen","year":"1997","journal-title":"Int J Cancer"},{"issue":"2","key":"2019111807383599000_B17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ijc.2910540208","article-title":"Relationship between the anti-HTLV-1 antibody level, the number of abnormal lymphocytes and the viral-genome dose in HTLV-1-infected individuals.","volume":"54","author":"Shinzato","year":"1993","journal-title":"Int J Cancer"},{"issue":"2","key":"2019111807383599000_B18","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4049\/jimmunol.133.2.1037","article-title":"Specific cytolysis of fresh tumor cells by an autologous killer T cell line derived from an adult T cell leukemia\/lymphoma patient.","volume":"133","author":"Kannagi","year":"1984","journal-title":"J Immunol"},{"issue":"6298","key":"2019111807383599000_B19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/348245a0","article-title":"Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.","volume":"348","author":"Jacobson","year":"1990","journal-title":"Nature"},{"issue":"1","key":"2019111807383599000_B20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.leu.2403176","article-title":"Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia\/lymphoma.","volume":"18","author":"Arnulf","year":"2004","journal-title":"Leukemia"},{"issue":"8","key":"2019111807383599000_B21","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.4049\/jimmunol.177.8.5718","article-title":"Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients.","volume":"177","author":"Kozako","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"2019111807383599000_B22","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1086\/315088","article-title":"Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection.","volume":"180","author":"Manns","year":"1999","journal-title":"J Infect Dis"},{"issue":"5","key":"2019111807383599000_B23","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1086\/506365","article-title":"Natural history of viral markers in children infected with human T lymphotropic virus type I in Jamaica.","volume":"194","author":"Maloney","year":"2006","journal-title":"J Infect Dis"},{"key":"2019111807383599000_B24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1742-4690-5-96","article-title":"Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP).","volume":"5","author":"Burbelo","year":"2008","journal-title":"Retrovirology"},{"issue":"5","key":"2019111807383599000_B25","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/ije\/25.5.1083","article-title":"A case-control study of risk factors for seropositivity to human T-lymphotropic virus type I (HTLV-I) in Jamaica.","volume":"25","author":"Murphy","year":"1996","journal-title":"Int J Epidemiol"},{"issue":"11","key":"2019111807383599000_B26","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/oxfordjournals.aje.a115824","article-title":"Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. I. Demographic determinants.","volume":"133","author":"Murphy","year":"1991","journal-title":"Am J Epidemiol"},{"key":"2019111807383599000_B27","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/00042560-199600001-00005","article-title":"Adult T-cell leukemia\/lymphoma in Jamaica: 1986-1995.","volume":"13","author":"Hanchard","year":"1996","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"2","key":"2019111807383599000_B28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00042560-199802010-00011","article-title":"Incidence of HTLV-I-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) in Jamaica and Trinidad.","volume":"17","author":"Maloney","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"8","key":"2019111807383599000_B29","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.38.8.1302","article-title":"Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy.","volume":"38","author":"Itoyama","year":"1988","journal-title":"Neurology"},{"issue":"2","key":"2019111807383599000_B30","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0165-5728(99)00175-7","article-title":"HTLV-I specific IFN-gamma+ CD8+ lymphocytes correlate with the proviral load in peripheral blood of infected individuals.","volume":"102","author":"Kubota","year":"2000","journal-title":"J Neuroimmunol"},{"issue":"3","key":"2019111807383599000_B31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood.V98.3.721","article-title":"High production of interferon gamma but not interleukin-2 by human T-lymphotropic virus type I-infected peripheral blood mononuclear cells.","volume":"98","author":"Hanon","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2019111807383599000_B32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood.V99.1.88","article-title":"Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM\/TSP).","volume":"99","author":"Yamano","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111807383599000_B33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/317932","article-title":"Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy\/tropical spastic paraparesis: correlation with HTLV-I provirus load.","volume":"183","author":"Nagai","year":"2001","journal-title":"J Infect Dis"},{"issue":"6","key":"2019111807383599000_B34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ana.10065","article-title":"Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM\/TSP.","volume":"50","author":"Nagai","year":"2001","journal-title":"Ann Neurol"},{"issue":"7","key":"2019111807383599000_B35","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1128\/JVI.65.7.3770-3778.1991","article-title":"In vivo genomic variability of human T-cell leukemia virus type I depends more upon geography than upon pathologies.","volume":"65","author":"Komurian","year":"1991","journal-title":"J Virol"},{"key":"2019111807383599000_B36","first-page":"4633s","article-title":"Comparative seroepidemiology of HTLV-I and HTLV-III in the French West Indies and some African countries.","volume":"45","author":"de-Th\u00e9","year":"1985","journal-title":"Cancer Res"},{"key":"2019111807383599000_B37","first-page":"5692S","article-title":"Epidemiology and immunovirology of human T-cell leukemia\/lymphoma virus type I-associated adult T-cell leukemia and chronic myelopathies as seen in France.","volume":"50","author":"Gessain","year":"1990","journal-title":"Cancer Res"},{"issue":"9","key":"2019111807383599000_B38","first-page":"699","article-title":"Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy\/tropical spastic paraparesis, and adult T-cell leukemia\/lymphoma.","volume":"5","author":"Giusti","year":"1996","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"2019111807383599000_B39","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1002\/ijc.21688","article-title":"Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia\/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors.","volume":"118","author":"Inagaki","year":"2006","journal-title":"Int J Cancer"},{"issue":"2","key":"2019111807383599000_B40","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2249.2006.03150.x","article-title":"Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)\/tropical spastic paraparesis (HAM\/TSP) disease from HTLV-1 carrier state.","volume":"145","author":"Guerreiro","year":"2006","journal-title":"Clin Exp Immunol"},{"issue":"1-2","key":"2019111807383599000_B41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jviromet.2009.05.007","article-title":"Performance of IgG and IgG1 anti-HTLV-1 reactivity by an indirect immunofluorescence flow cytometric assay for the identification of persons infected with HTLV-1, asymptomatic carriers and patients with myelopathy.","volume":"160","author":"Coelho-dos-Reis","year":"2009","journal-title":"J Virol Methods"},{"issue":"6","key":"2019111807383599000_B42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/erv.10.50","article-title":"Antibody-profiling technologies for studying humoral responses to infectious agents.","volume":"9","author":"Burbelo","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"2019111807383599000_B43","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1039\/c0mb00342e","article-title":"LIPS arrays for simultaneous detection of antibodies against partial and whole proteomes of HCV, HIV and EBV.","volume":"7","author":"Burbelo","year":"2011","journal-title":"Mol Biosyst"},{"issue":"1-3","key":"2019111807383599000_B44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0165-5728(91)90171-3","article-title":"Elevated antibodies to synthetic peptides of HTLV-1 envelope transmembrane glycoproteins in patients with HAM\/TSP.","volume":"35","author":"Nakamura","year":"1991","journal-title":"J Neuroimmunol"},{"issue":"10","key":"2019111807383599000_B45","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1349-7006.2004.tb02190.x","article-title":"Novel biomarker of HTLV-1-associated disease: specific appearance of antibody recognizing the receptor-binding site on HTLV-1 envelope protein.","volume":"95","author":"Sagara","year":"2004","journal-title":"Cancer Sci"},{"issue":"8","key":"2019111807383599000_B46","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2169\/internalmedicine.34.713","article-title":"Human T lymphotropic virus type I (HTLV-I)-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP): recent perspectives.","volume":"34","author":"Ijichi","year":"1995","journal-title":"Intern Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/12\/2829\/1351249\/zh801212002829.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/12\/2829\/1351249\/zh801212002829.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T11:46:28Z","timestamp":1686743188000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/12\/2829\/29875\/Quantitative-differences-in-HTLVI-antibody"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,22]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,3,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-11-390807","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,22]]}}}